Connect with us

Spread & Containment

3 Short Squeeze Penny Stocks To Buy For Under $5 This Week

Short squeeze penny stocks to watch this week.
The post 3 Short Squeeze Penny Stocks To Buy For Under $5 This Week appeared first on Penny Stocks to Buy,…

Published

1 year ago

on

The stock market crash continues this week, with shares of companies retreating on Monday morning. Investors are taking bearish bets that inflation may not have peaked. Meanwhile, supply chain issues remain a factor, and headwinds persist from last week’s Fed meeting. Whether it’s penny stocks or mega-cap names like Microsoft (NASDAQ: MSFT), selling pressure is taking most stocks lower. However, something else this bearish sentiment has done is put a heavy focus on stocks with short interest.

Those of you who’ve traded since the beginning of the pandemic know this scenario all too well. Companies like AMC Entertainment (NYSE: AMC) and GameStop (NYSE: GME) were already experiencing significant selling pressure. The global pandemic heightened this pressure allowing Wall Street Firms to lean into already beaten-down names. Retail traders saw this as a high sign to teach a lesson for “hitting the little guy when they’re down,” and some of the most significant short squeezes in recent history would ensue.

Fast-forward to 2022, and a similar situation is unfolding. The stock market crash has taken countless stocks lower and led to higher levels of short interest. Despite the current market conditions, some traders are already on the hunt for potential short squeeze stocks to add to their list when the stock market rebounds. Today we look at a handful of penny stocks with high short interest.

Penny Stocks To Buy [or avoid]

1. PAVMed Inc. (NASDAQ: PAVM)

PAVMed has experienced a steep decline in a shorter period. At the start of Q4, 2021, PAVM stock traded north of $8 per share. This quarter, its shares hit new 52-week lows of $0.94. Much of the focus has been on PAVMed’s Lucid Diagnostics (NASDAQ: LUCD) subsidiary. Large capital raises and a class action suit have outshined even the brightest spots over the last few months. Nevertheless, PAVMed and Lucid continue to press on, and this week has already become one of interest for the market.

PAVM Stock News

Both Lucid and PAVMed are set to hold back-to-back business update calls this week. Lucid hosts its on May 11th, followed by PAVMed’s on May 12th. The two will discuss their near-term milestones and growth strategies in addition to Q1 2022 financial results. These presentations will come shortly after Lucid’s LucidDx Labs secured a participating provider agreement with MediNcrease Health Plans, a provider network with more than 8 million lives covered.

Those covered by MediNcrease clients and payers will have access to Lucid’s EsoGuard® DNA test. This is the company’s tool to prevent esophageal cancer deaths through early detection of esophageal precancer.

Is PAVM A Short Squeeze Stock?

Shares of PAVM stock are down significantly since last September. Has that amounted to a sizeable short position? According to Fintel.IO data, the current PAVM stock short float percentage is 9.13%.

2. Medavail Holdings Inc. (NASDAQ: MDVL)

Unlike PAVMed, Medavail has enjoyed a bullish move in the stock market this quarter. You might recall this company being mentioned back in April on one of our penny stocks watch lists. At the time, MDVL stock was on the radar thanks to strong insider buying activity from one of its 10% owners, Ally Bridge Group. The company is a technology-enabled pharmacy organization that offers in-clinic pharmacy services through robotic dispensing platforms.

MDVL Stock News

As far as recent MDVL stock news, the market appears to be focused on what’s coming this week. Medavail delivers its next round of earnings results on Thursday after the market closes. Traders will likely be paying attention to see if the company was able to continue growing during the quarter. In Q4 of 2021, Medavail recorded a 170% increase in retail pharmacy services revenue and a total revenue figure of $7.3 million. MedAvail also said that it expects total revenue for Q1 2022 to be “in excess” of $8.8 million. That would be more than double its total revenue in the same period in 2021.

Stock Market Crash: 4 Penny Stocks To Watch As Dow Slides

Is MDVL A Short Squeeze Stock?

The volatility in MDVL stock has been apparent over the last month. But can that be attributed to traders playing the short? According to data from Fintel, the short float percentage sits at 21.86%.

short squeeze penny stocks to buy Medavail MDVL stock chart

3. Blue Apron Holdings Inc. (NYSE: APRN)

Meal-kit company Blue Apron has experienced a whirlwind last few quarters. Traders have seen this stock rise to highs of over $12.70 and plummet to fresh 52-week lows of $2.85 within months. The latest slide comes after a $70.5 million debt and equity arrangement from investors, including Blue Apron CEO Linda Findley. The aim is to have enough capital to continue executing the turnaround strategies that the company previously outlined.

Recent APRN Stock News

Once again, the news is acting as a catalyst during today’s stock market crash. Shares have promptly bounced from premarket lows of $2.80 to intra-day highs of over $3.30 after Blue Apron’s latest earnings results were posted. The company missed earnings per share and sales. However, the company highlighted that it expects a return to positive year-over-year net revenue growth starting this quarter.

“When we complete the expected remaining $20.0 million private placement transaction at the end of this month, we expect to have approximately $80 million in cash, and we expect positive operating cash flow this quarter. Proceeds from the transactions are expected to support our continued turnaround as we drive towards long-term sustainable growth.”

Randy Greben, Blue Apron’s Chief Financial Officer

Is APRN A Short Squeeze Stock?

With such a sharp decline in a short period, the chances were high for APRN to have amassed higher short interest. However, a more direct look at data from Fintel shows the bigger picture. The APRN short float percentage sits at 33.99%.

short squeeze penny stocks to buy Blue Apron APRN stock chart

Top Penny Stocks To Buy Now?

If you’re looking for the top penny stocks to buy now, you’ve got your work cut out for you. Higher levels of stock market volatility have given way to massive price fluctuations. Current conditions in the stock market today aren’t for the timid especially if penny stocks are your focus.

Interesting in learning more about penny stocks and the stock market as a whole? Check out True Trading Group the fastest growing & highest-rated online premium educational platform available today and a 7-day Trial of its platform for free. To Learn More Click Here.

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

The post 3 Short Squeeze Penny Stocks To Buy For Under $5 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Related Topics:
Continue Reading

Spread & Containment

Removing antimicrobial resistance from the WHO’s ‘pandemic treaty’ will leave humanity extremely vulnerable to future pandemics

Drug-resistant microbes are a serious threat for future pandemics, but the new draft of the WHO’s international pandemic agreement may not include provisions…

Published

6 hours ago

on

June 4, 2023

By

Antimicrobial resistance is now a leading cause of death worldwide due to drug-resistant infections, including drug-resistant strains of tuberculosis, pneumonia and Staph infections like the methicillin-resistant Staphylococcus aureus shown here. (NIAID, cropped from original), CC BY

In late May, the latest version of the draft Pandemic Instrument, also referred to as the “pandemic treaty,” was shared with Member States at the World Health Assembly. The text was made available online via Health Policy Watch and it quickly became apparent that all mentions of addressing antimicrobial resistance in the Pandemic Instrument were at risk of removal.

Work on the Pandemic Instrument began in December 2021 after the World Health Assembly agreed to a global process to draft and negotiate an international instrument — under the Constitution of the World Health Organization (WHO) — to protect nations and communities from future pandemic emergencies.

Read more: Drug-resistant superbugs: A global threat intensified by the fight against coronavirus

Since the beginning of negotiations on the Pandemic Instrument, there have been calls from civil society and leading experts, including the Global Leaders Group on Antimicrobial Resistance, to include the so-called “silent” pandemic of antimicrobial resistance in the instrument.

Just three years after the onset of a global pandemic, it is understandable why Member States negotiating the Pandemic Instrument have focused on preventing pandemics that resemble COVID-19. But not all pandemics in the past have been caused by viruses and not all pandemics in the future will be caused by viruses. Devastating past pandemics of bacterial diseases have included plague and cholera. The next pandemic could be caused by bacteria or other microbes.

Antimicrobial resistance

Yellow particles on purple spikes
Microscopic view of Yersinia pestis, the bacteria that cause bubonic plague, on a flea. Plague is an example of previous devastating pandemics of bacterial disease. (NIAID), CC BY

Antimicrobial resistance (AMR) is the process by which infections caused by microbes become resistant to the medicines developed to treat them. Microbes include bacteria, fungi, viruses and parasites. Bacterial infections alone cause one in eight deaths globally.

AMR is fueling the rise of drug-resistant infections, including drug-resistant tuberculosis, drug-resistant pneumonia and drug-resistant Staph infections such as methicillin-resistant Staphylococcus aureus (MRSA). These infections are killing and debilitating millions of people annually, and AMR is now a leading cause of death worldwide.

Without knowing what the next pandemic will be, the “pandemic treaty” must plan, prepare and develop effective tools to respond to a wider range of pandemic threats, not solely viruses.

Even if the world faces another viral pandemic, secondary bacterial infections will be a serious issue. During the COVID-19 pandemic for instance, large percentages of those hospitalized with COVID-19 required treatment for secondary bacterial infections.

New research from Northwestern University suggests that many of the deaths among hospitalized COVID-19 patients were associated with pneumonia — a secondary bacterial infection that must be treated with antibiotics.

An illustrative diagram that shows the difference between a drug resistant bacteria and a non-resistant bacteria.
Antimicrobial resistance means infections that were once treatable are much more difficult to treat. (NIAID), CC BY

Treating these bacterial infections requires effective antibiotics, and with AMR increasing, effective antibiotics are becoming a scarce resource. Essentially, safeguarding the remaining effective antibiotics we have is critical to responding to any pandemic.

That’s why the potential removal of measures that would help mitigate AMR and better safeguard antimicrobial effectiveness is so concerning. Sections of the text which may be removed include measures to prevent infections (caused by bacteria, viruses and other microbes), such as:

  • better access to safe water, sanitation and hygiene;
  • higher standards of infection prevention and control;
  • integrated surveillance of infectious disease threats from human, animals and the environment; and
  • strengthening antimicrobial stewardship efforts to optimize how antimicrobial drugs are used and prevent the development of AMR.

The exclusion of these measures would hinder efforts to protect people from future pandemics, and appears to be part of a broader shift to water-down the language in the Pandemic Instrument, making it easier for countries to opt-out of taking recommended actions to prevent future pandemics.

Making the ‘pandemic treaty’ more robust

Measures to address AMR could be easily included and addressed in the “pandemic treaty.”

In September 2022, I was part of a group of civil society and research organizations that specialize in mitigating AMR who were invited the WHO’s Intergovernmental Negotiating Body (INB) to provide an analysis on how AMR should be addressed, within the then-draft text.

They outlined that including bacterial pathogens in the definition of “pandemics” was critical. They also identified specific provisions that should be tweaked to track and address both viral and bacterial threats. These included AMR and recommended harmonizing national AMR stewardship rules.

In March 2023, I joined other leading academic researchers and experts from various fields in publishing a special edition of the Journal of Medicine, Law and Ethics, outlining why the Pandemic Instrument must address AMR.

The researchers of this special issue argued that the Pandemic Instrument was overly focused on viral threats and ignored AMR and bacterial threats, including the need to manage antibiotics as a common-pool resource and revitalize research and development of novel antimicrobial drugs.

Next steps

While earlier drafts of the Pandemic Instrument drew on guidance from AMR policy researchers and civil society organizations, after the first round of closed-door negotiations by Member States, all of these insertions, are now at risk for removal.

The Pandemic Instrument is the best option to mitigate AMR and safeguard lifesaving antimicrobials to treat secondary infections in pandemics. AMR exceeds the capacity of any single country or sector to solve. Global political action is needed to ensure the international community works together to collectively mitigate AMR and support the conservation, development and equitable distribution of safe and effective antimicrobials.

By missing this opportunity to address AMR and safeguard antimicrobials in the Pandemic Instrument, we severely undermine the broader goals of the instrument: to protect nations and communities from future pandemic emergencies.

It is important going forward that Member States recognize the core infrastructural role that antimicrobials play in pandemic response and strengthen, rather than weaken, measures meant to safeguard antimicrobials.

Antimicrobials are an essential resource for responding to pandemic emergencies that must be protected. If governments are serious about pandemic preparedness, they must support bold measures to conserve the effectiveness of antimicrobials within the Pandemic Instrument.

Susan Rogers Van Katwyk is a member of the WHO Collaborating Centre on Global Governance of Antimicrobial Resistance at York University. She receives funding from the Wellcome Trust and the Social Sciences and Humanities Research Council of Canada.

Read More

Continue Reading

Spread & Containment

Repeated COVID-19 Vaccination Weakens Immune System: Study

Repeated COVID-19 Vaccination Weakens Immune System: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Repeated COVID-19…

Published

14 hours ago

on

June 3, 2023

By

Repeated COVID-19 Vaccination Weakens Immune System: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Repeated COVID-19 vaccination weakens the immune system, potentially making people susceptible to life-threatening conditions such as cancer, according to a new study.

A man is given a COVID-19 vaccine in Chelsea, Mass., on Feb. 16, 2021. (Joseph Prezioso/AFP via Getty Images)

Multiple doses of the Pfizer or Moderna COVID-19 vaccines lead to higher levels of antibodies called IgG4, which can provide a protective effect. But a growing body of evidence indicates that the “abnormally high levels” of the immunoglobulin subclass actually make the immune system more susceptible to the COVID-19 spike protein in the vaccines, researchers said in the paper.

They pointed to experiments performed on mice that found multiple boosters on top of the initial COVID-19 vaccination “significantly decreased” protection against both the Delta and Omicron virus variants and testing that found a spike in IgG4 levels after repeat Pfizer vaccination, suggesting immune exhaustion.

Studies have detected higher levels of IgG4 in people who died with COVID-19 when compared to those who recovered and linked the levels with another known determinant of COVID-19-related mortality, the researchers also noted.

A review of the literature also showed that vaccines against HIV, malaria, and pertussis also induce the production of IgG4.

“In sum, COVID-19 epidemiological studies cited in our work plus the failure of HIV, Malaria, and Pertussis vaccines constitute irrefutable evidence demonstrating that an increase in IgG4 levels impairs immune responses,” Alberto Rubio Casillas, a researcher with the biology laboratory at the University of Guadalajara in Mexico and one of the authors of the new paper, told The Epoch Times via email.

The paper was published by the journal Vaccines in May.

Pfizer and Moderna officials didn’t respond to requests for comment.

Both companies utilize messenger RNA (mRNA) technology in their vaccines.

Dr. Robert Malone, who helped invent the technology, said the paper illustrates why he’s been warning about the negative effects of repeated vaccination.

“I warned that more jabs can result in what’s called high zone tolerance, of which the switch to IgG4 is one of the mechanisms. And now we have data that clearly demonstrate that’s occurring in the case of this as well as some other vaccines,” Malone, who wasn’t involved with the study, told The Epoch Times.

“So it’s basically validating that this rush to administer and re-administer without having solid data to back those decisions was highly counterproductive and appears to have resulted in a cohort of people that are actually more susceptible to the disease.”

Possible Problems

The weakened immune systems brought about by repeated vaccination could lead to serious problems, including cancer, the researchers said.

Read more here...

Tyler Durden Sat, 06/03/2023 - 22:30

Read More

Continue Reading

Spread & Containment

Robert F. Kennedy Jr. Banned By Major Social Media Site, Campaign Pages Blocked

Robert F. Kennedy Jr. Banned By Major Social Media Site, Campaign Pages Blocked

Authored by Jack Phillips via The Epoch Times (emphasis ours),

Twitter…

Published

15 hours ago

on

June 3, 2023

By

Robert F. Kennedy Jr. Banned By Major Social Media Site, Campaign Pages Blocked

Authored by Jack Phillips via The Epoch Times (emphasis ours),

Twitter owner Elon Musk invited Democrat presidential candidate Robert F. Kennedy Jr. for a discussion on his Twitter Spaces after Kennedy said his campaign was suspended by Meta-owned Instagram.

“Interesting… when we use our TeamKennedy email address to set up @instagram accounts we get an automatic 180-day ban. Can anyone guess why that’s happening?” he wrote on Twitter.

An accompanying image shows that Instagram said it “suspended” his “Team Kennedy” account and that there “are 180 days remaining to disagree” with the company’s decision.

Robert F. Kennedy, Jr. attends Keep it Clean to benefit Waterkeeper Alliance in Los Angeles, Calif., on March 1, 2018. (John Sciulli/Getty Images for Waterkeeper Alliance)

In response to his post, Musk wrote: “Would you like to do a Spaces discussion with me next week?” Kennedy agreed, saying he would do it Monday at 2 p.m. ET.

Hours later, Kennedy wrote that Instagram “still hasn’t reinstated my account, which was banned years ago with more than 900k followers.” He argued that “to silence a major political candidate is profoundly undemocratic.”

“Social media is the modern equivalent of the town square,” the candidate, who is the nephew of former President John F. Kennedy, wrote. “How can democracy function if only some candidates have access to it?”

The Epoch Times approached Instagram for comment.

It’s not the first time that either Facebook or Instagram has taken action against Kennedy. In 2021, Instagram banned him from posting claims about vaccine safety and COVID-19.

After he was banned by the platform, Kennedy said that his Instagram posts raised legitimate concerns about vaccines and were backed by research. His account was banned just days after Facebook and Instagram announced they would block the spread of what they described as misinformation about vaccines, including research saying the shots cause autism, are dangerous, or are ineffective.

“This kind of censorship is counterproductive if our objective is a safe and effective vaccine supply,” he said at the time.

Read more here...

Tyler Durden Sat, 06/03/2023 - 20:30

Read More

Continue Reading

Trending